Nanocarrier-based topical drug delivery for an antifungal drug

Drug Development and Industrial Pharmacy

Volumn 40, Issue 4, 2014, Pages 527-541

  Hussain, Afzal ^a   Samad, Abdus ^b   Nazish, Iram ^c   Ahmed, Farhan Jalees ^c  

^a GURU NANAK DEV UNIVERSITY   (India)

^b Fortis Clinical Research Ltd   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

Amphotericin B; Enhanced skin permeation; Nanoemulsion; Topical drug delivery

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; DIMETHYL SULFOXIDE; HEMOGLOBIN; NANOCARRIER; PROPYLENE GLYCOL; SURFACTANT;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BLOOD ANALYSIS; BODY WEIGHT; BRIGHT FIELD MICROSCOPY; CELL SUSPENSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUTION; ERYTHROCYTE; EX VIVO STUDY; FLUID INTAKE; FOOD INTAKE; FREEZE THAWING; HEMOLYSIS; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOEMULSION; NONHUMAN; NORMAL HUMAN; PARTICLE SIZE; PHASE SEPARATION; PRECIPITATION; RAT; SKIN; SOLUBILITY; SOLUBILIZATION; STEADY STATE; SURFACE TENSION; SURVIVAL; THERMODYNAMICS; THERMOSTABILITY; THIN LAYER CHROMATOGRAPHY; TOXICITY; TRANSMISSION ELECTRON MICROSCOPY; VISCOMETRY; VISCOSITY; ZETA POTENTIAL;

ADMINISTRATION, CUTANEOUS; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; FEMALE; MALE; MICE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SKIN; SKIN ABSORPTION; SURFACE-ACTIVE AGENTS; THERMODYNAMICS;

EID: 84896717214     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.771647     Document Type: Article

References (28)

1. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
2. Gerbaud E, Tamion F, Girault C, et al. Persistent acute tubular toxicity after switch from conventional amphotericin B to liposomal amphotericin B (Ambosome). J Antimicrob Chemother 2003;51: 473-5.
3. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis pf liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000;18:2476-83.
4. Osborne DW, Ward AJ, Neil KJ. Microemulsions as topical delivery vehicles: in-vitro transdermal studies of a model hydrophilic drug. J Pharm Phamacol 1991;43:450-4.
5. Trotta M, Pattarino F, Gasco MR. Influence of counter ions on the skin permeation of methotrexate from water-oil microemulsions. Pharm Acta Helv 1996;71:135-40.
6. Azeem A, Rizwan M, Ahmad FJ, et al. Nanoemulsion components screening and selection: a technical note. AAPS PharmSci Tech 2009;10:69.
7. Porter CJ, Pouton CW. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev 2008;60:625-37.
8. Eccleston J. Microemulsions. In: Swarbrick J, Boylan JC, eds. Encyclopedia of pharmaceutical technology. Vol. 9. New York: Marcel Dekker; 1994:375-421.
9. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000;45:89-121.
10. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev 1997;25:47-58.
11. Khoo SM, Humberstone AJ, Porter CJH, et al. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm 1998;167:155-64.
12. Attwood D, Mallon D, Taylor CJ. Phase studies on oil in water microemulsions. Int J Pharm 1992;8:R5-8.
13. Skalko N, Cajkovac M, Jals?enjak I. Liposomes with metronidazole for topical use: the choice of preparation method and vehicle. J Liposome Res 1998;8:283-93.
14. Perkins WR, Minchey SR, Boni LT, et al. Amphotericin B phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Bio-phys Acta 1992;1107:271-82.
15. OECD (The organization of Economic Co-operation Development), The OECD Guideline for testing of chemicals: 420 Acute Oral Toxicity. OECD, Paris. 2000;1e:14.
16. Langevin D. Microemulsions. Acc Chem Res 1988;21:255-60.
17. Ghosh PK, Murthy RS. Microemulsions: a potential drug delivery system. Curr Drug Deliv 2006;3:167-80.
18. Krishnaiah YS, Satyanarayana V, Karthikeyan RS. Effect of the solvent system on the in vitro permeability of nicardipine hydrochloride through excised rat epidermis. J Pharm Sci 2002;5: 123-30.
19. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603-18.
20. Tashtoush BM, Al-Safi SA, Al-Fanek KJ. Azathioprine transport through rat skin and its immunosuppressive effect. Pharmazie 2004; 59:143-6.
21. Reddy LH, Ghosh B. Enhancer aided in vitro permeation of atenolol and prazosin hydro-chloride through mice skin. Indian J Exp Biol 2001;39:47-51.
22. Godwin DA, Michniak BB, Creek KE. Evaluation of transdermal penetration enhancers using a novel skin alternative. J Pharm Sci 1997;86:1001-5.
23. Shin SC, Choi JS. Enhanced efficacy of triprolidine by transdermal application of the EVA matrix system in rabbits and rats. Eur J Pharm Biopharm 2005;61:14-19.
24. Deray G. Amphotericin B nephrotoxicity. J. Antimicrob Chemother 2002;49:37-41.
25. Falk R, Domb AJ, Polacheck I. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob Agents Chemother 1999;43:1975-81.
26. Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997;41:2089-92.
27. Maddux MS, Barriere AL. A review of complications of amphotericin B therapy: recommendations for prevention and management. Drug Intel Clin Pharm 1980;14:177-81.
28. Danaher PJ, Cao MK, Anstead GM, et al. Reversible dilated cardiomyopathy related to amphotericin B therapy. J Antimicrob Chemother 2004;53:115-17.